Center For Scientific Review; Notice of Closed Meetings, 69632-69633 [2020-24306]
Download as PDF
<![CDATA[
69632
Federal Register / Vol. 85, No. 213 / Tuesday, November 3, 2020 / Notices
that minimize undue negative impacts
of customer and sequence screening on
the synthetic biology industry and the
life sciences research community. The
following questions are meant to elicit
insights into how these responsibilities
may have impacted synthetic dsDNA
providers and customers.
Does implementation of the current
Guidance unduly burden providers of
synthetic dsDNA? If so, how could it be
modified without compromising
effectiveness?
Have customers experienced delays in
receiving orders of synthetic dsDNA due
to screening?
Have there been any undue burdens,
financial, logistical, or otherwise since
implementing the Guidance? If so, has
it increased, especially as other costs
associated with dsDNA synthesis have
decreased?
What challenges, if any, do the
recommendation to retain records of
customer orders, ‘‘hits,’’ and/or followup screening for at least eight years
present for your organization?
How might potential changes to the
Guidance to expand the scope or
methodologies affect the burden for
providers of dsDNA and customers
(including delays to scientific progress
caused by extended review)?
Is your organization concerned about
legal liability challenges between
customers and providers?
khammond on DSKJM1Z7X2PROD with NOTICES
Technologies Subject to the Guidance
The Guidance currently addresses
only synthetic dsDNA and it was
developed based on providers’ existing
protocols and technologies at that time.
The life sciences field is rapidly
advancing through improved
bioinformatics tools, new technologies,
and new discoveries. The following
questions pertain to how the Guidance
could be modified to address the new
biosecurity risks that may be posed by
advances in the life sciences.
Do other oligonucleotide types and
other synthetic biological technologies,
currently not covered by the Guidance,
pose similar biosecurity risks as
synthetic dsDNA (e.g., Ribonucleic Acid
[RNA], single-stranded DNA, or other
oligonucleotides)?
Are there other appropriate security
measures that should be established to
address the potential threats arising
from the use of nucleic acid synthesis,
given new and emerging technologies in
the life sciences?
Are there new biosecurity risks posed
by the introduction of new generations
of benchtop DNA synthesizers capable
of synthesizing and assembling dsDNA,
RNA, single-stranded DNA, or
VerDate Sep<11>2014
16:55 Nov 02, 2020
Jkt 253001
oligonucleotides in-house that should
be addressed by the Guidance?
As synthetic biology becomes an
increasingly digital enterprise with large
databases, digital tools, robotics, and
artificial intelligence, what new risks
are presented to providers and
consumers of synthetic
oligonucleotides?
If new risks are evident, how should
these risks be addressed, keeping in
mind the potential impacts on
providers, customers, and scientific
progress?
Additional Considerations
The U.S. Government is committed to
mitigating the potential biosecurity risks
associated with synthetic DNA and its
applications, while minimizing undue
impacts on providers, customers, and
scientific progress.
Are there other mechanisms that the
U.S. Government should consider for
screening sequences, customers, or enduses that may help mitigate the
biosecurity risks associated with
synthetic nucleotides and their
applications, while minimizing undue
impacts on providers, customers, and
scientific progress?
Authority: Section 301 of the Public Health
Service Act, 42 U.S.C. 241; Section 605 of the
Pandemic and All-Hazards Preparedness and
Advancing Innovation Act of 2019, Pub. L.
116–22.
Dated: October 28, 2020.
Robert P. Kadlec,
Assistant Secretary for Preparedness and
Response.
[FR Doc. 2020–24265 Filed 11–2–20; 8:45 am]
BILLING CODE 4150–37–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Lung Diseases.
Date: November 24–25, 2020.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: George M. Barnas, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4220,
MSC 7818, Bethesda, MD 20892, (301) 435–
0696, barnasg@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Vascular Pathobiology.
Date: November 30–December 1, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Ai-Ping Zou, MD, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4118,
MSC 7814, Bethesda, MD 20892, (301) 408–
9497, zouai@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Review of
R21 Applications: RFA–OD–19–021.
Date: November 30, 2020.
Time: 2:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Atul Sahai, Ph.D.,
Scientific Review, Officer Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2188,
MSC 7818, Bethesda, MD 20892, (301) 435–
1198, sahaia@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Cancer Biology.
Date: November 30, 2020.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Rolf Jakobi, Ph.D.,
Scientific Review, Officer Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6187,
MSC 7806, Bethesda, MD 20892, (301) 495–
1718, jakobir@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine,
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
E:\FR\FM\03NON1.SGM
03NON1
Federal Register / Vol. 85, No. 213 / Tuesday, November 3, 2020 / Notices
Dated: October 28, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24306 Filed 11–2–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel,
November 19, 2020, 1 p.m. to November
19, 2020, 5 p.m., National Institutes of
Health, 6701 Rockledge Drive, Bethesda,
MD 20892 which was published in the
Federal Register on October 22, 2020,
85 FR 67361.
This notice is being amended to
change the panel name from Aspects of
Development and Disease in the Cornea
to Member Conflict: Neuropsychiatric
Disorders. The meeting is closed to the
public.
Dated: October 28, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24256 Filed 11–2–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Topics in
Instrumentation and Systems Development.
Date: November 19, 2020.
Time: 11:00 a.m. to 12:30 p.m.
VerDate Sep<11>2014
16:55 Nov 02, 2020
Jkt 253001
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Kee Forbes, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5148,
MSC 7806, Bethesda, MD 20892, 301–272–
4865, kee.forbes@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 19–
294: Early-Stage Preclinical Validation of
Therapeutic Leads for Diseases of Interest to
the NIDDK.
Date: December 1–2, 2020.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Raul Rojas, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6185,
Bethesda, MD 20892, (301) 451–6319, rojasr@
mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Sleep, Stress, Olfactory and Spatial
Processing.
Date: December 1, 2020.
Time: 12:01 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Janita N. Turchi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5185,
Bethesda, MD 20892, (301) 402–4005,
turchij@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Research
Related to Coronavirus Disease 2019
(COVID–19).
Date: December 2, 2020.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Baishali Maskeri, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2022,
Bethesda, MD 20892, 301–827–2864,
maskerib@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR20–103:
Collaborative Program Grant for
Multidisciplinary Teams (RM1).
Date: December 2, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
69633
Contact Person: William A. Greenberg,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4168,
MSC 7806, Bethesda, MD 20892, (301) 435–
1726, greenbergwa@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Pathogenic
Eukaryotes.
Date: December 2, 2020.
Time: 10:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Tera Bounds, Ph.D., DVM,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3198,
MSC 7808, Bethesda, MD 20892, (301) 435–
2306, boundst@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Neurobiology of Glia.
Date: December 2, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Peter B. Guthrie, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4142,
MSC 7850, Bethesda, MD 20892, (301) 435–
1239, guthriep@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 29, 2020.
Patricia B. Hansberger,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2020–24368 Filed 11–2–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
E:\FR\FM\03NON1.SGM
03NON1
]]>Agencies
[Federal Register Volume 85, Number 213 (Tuesday, November 3, 2020)]
[Notices]
[Pages 69632-69633]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-24306]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Lung Diseases.
Date: November 24-25, 2020.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).
Contact Person: George M. Barnas, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4220, MSC 7818, Bethesda, MD
20892, (301) 435-0696, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Member Conflict: Vascular Pathobiology.
Date: November 30-December 1, 2020.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Ai-Ping Zou, MD, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4118, MSC 7814, Bethesda, MD
20892, (301) 408-9497, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Review of R21 Applications: RFA-OD-19-021.
Date: November 30, 2020.
Time: 2:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Atul Sahai, Ph.D., Scientific Review, Officer
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 2188, MSC 7818, Bethesda, MD 20892, (301) 435-
1198, [email protected].
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Member Conflict: Cancer Biology.
Date: November 30, 2020.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Rolf Jakobi, Ph.D., Scientific Review, Officer
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 6187, MSC 7806, Bethesda, MD 20892, (301) 495-
1718, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine, 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
[[Page 69633]]
Dated: October 28, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-24306 Filed 11-2-20; 8:45 am]
BILLING CODE 4140-01-P
